Literature DB >> 20667970

Temsirolimus: is improved survival the correct expression of drug activity?

Michele Basso, Alessandra Cassano, Giovanni Schinzari, Carlo Barone.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20667970      PMCID： PMC3228000          DOI： 10.1634/theoncologist.2010-0099

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  6 in total

1.  FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma.

Authors:  Virginia E Kwitkowski; Tatiana M Prowell; Amna Ibrahim; Ann T Farrell; Robert Justice; Shan Sun Mitchell; Rajeshwari Sridhara; Richard Pazdur
Journal:  Oncologist       Date:  2010-03-23

2.  Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.

Authors:  S Pyrhönen; E Salminen; M Ruutu; T Lehtonen; M Nurmi; T Tammela; H Juusela; E Rintala; P Hietanen; P L Kellokumpu-Lehtinen
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

3.  Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials.

Authors:  Daniel J Sargent; Harry S Wieand; Daniel G Haller; Richard Gray; Jacqueline K Benedetti; Marc Buyse; Roberto Labianca; Jean Francois Seitz; Christopher J O'Callaghan; Guido Francini; Axel Grothey; Michael O'Connell; Paul J Catalano; Charles D Blanke; David Kerr; Erin Green; Norman Wolmark; Thierry Andre; Richard M Goldberg; Aimery De Gramont
Journal:  J Clin Oncol       Date:  2005-10-31       Impact factor: 44.544

4.  Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

Authors:  David F McDermott; Meredith M Regan; Joseph I Clark; Lawrence E Flaherty; Geoffery R Weiss; Theodore F Logan; John M Kirkwood; Michael S Gordon; Jeffrey A Sosman; Marc S Ernstoff; Christopher P G Tretter; Walter J Urba; John W Smith; Kim A Margolin; James W Mier; Jared A Gollob; Janice P Dutcher; Michael B Atkins
Journal:  J Clin Oncol       Date:  2005-01-01       Impact factor: 44.544

Review 5.  Renal cell carcinoma.

Authors:  Brian I Rini; Steven C Campbell; Bernard Escudier
Journal:  Lancet       Date:  2009-03-05       Impact factor: 79.321

6.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Authors:  Gary Hudes; Michael Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245
  6 in total
  1 in total

Review 1.  First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature Review.

Authors:  Olivia Le Saux; Gilles Freyer; Sylvie Négrier
Journal:  Clin Drug Investig       Date:  2016-05       Impact factor: 2.859
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.